News & Events about Twist Bioscience Corp.
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced publication of preclinical data supporting the potential use of the highly potent and optimized GLP-1R antagonist...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the second quarter of fiscal 2023 ended March 31, 2023. We reported a...
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Twist Bioscience Corp (NASDAQ: TWST) on behalf of long-term stockholders following a class action complaint that was filed against Twist on December 12, 2022 with a...
SAN DIEGO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Twist Bioscience Corporation (NASDAQ: TWST). Investors who purchased shares of Twist Bioscience Corporation long term and continue to hold any of ...
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Twist Bioscience Corporation (NASDAQ: TWST) between December 13, 2019 and November 14, 2022, both dates inclusive (the Class Period), of the important February 10, 2023 lead plaintiff deadline. SO WHAT...